GlassScriptPhysician profile
Daniel J Irizarry
NPI 1477561843
$1,058.65
in general payments reported to CMS, 2019-2025
21 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.31 · 2020: $94.18 · 2021: $275 · 2022: $249 · 2023: $279 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $402.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $142.66 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $123.31 | 2025 | |
| Esperion Therapeutics, INC. | $100.14 | 2021 | |
| Sanofi-Aventis U.S. LLC | $91.08 | 2023 | |
| Glaxosmithkline, LLC. | $83.70 | 2020-2022 | |
| Abbvie INC. | $74.38 | 2021-2023 | |
| Abbott Laboratories | $57.24 | 2019-2023 | Proclaim |
| Pfizer INC. | $50.82 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $50.03 | 2022 | |
| Phadia US INC. | $47.73 | 2022-2023 | Immunocap |
| Coala Life INC | $36.34 | 2023 | Coala Heart Monitor |
| Genentech USA, INC. | $35.76 | 2020-2021 | |
| Daiichi Sankyo INC. | $29.28 | 2020-2021 | |
| Medtronic, INC. | $23.93 | 2023 | Closurefast |
| Photonicare INC | $19.74 | 2023 | Otosight Middle Ear Scope |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $19.69 | 2022 | |
| Novo Nordisk INC | $19.33 | 2022 | |
| Organogenesis INC. | $16.20 | 2023 | Puraply |
| Viiv Healthcare Company | $14.48 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.71 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Irizarry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.